STOCK TITAN
  1. Home
  2. Sec-filings
  3. EXOZ
  4. [8-K] EXOZYMES INC. Reports Material Event

eXoZymes (EXOZ) files investor presentation tied to proposed securities offering

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

eXoZymes Inc.

Positive

  • None.

Negative

  • None.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Investor Presentation financial
"Attached is an Investor Presentation of eXoZymes Inc., a Nevada corporation, as of April 10, 2026"
An investor presentation is a carefully prepared talk or visual display that explains a company's business, goals, and financial performance. It helps investors understand how the company operates and its future prospects, much like a report card or progress update. These presentations are important because they provide transparency and help investors decide whether to support or invest in the company.
proposed offering of securities financial
"for the proposed offering of securities by the Company"
Nasdaq Capital Market financial
"Common Stock | | EXOZ | | Nasdaq Capital Market"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Understanding 8-K Material Events →
false 0002010788 0002010788 2026-04-10 2026-04-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

Current Report Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):

April 10, 2026

 

EXOZYMES INC.

(Exact name of registrant as specified in its charter)

 

Nevada   001-42204   83-4550057

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

750 Royal Oaks Drive, Suite 106

Monrovia, CA 91016

(Address of principal executive offices and zip code)

 

Registrant’s telephone number, including area code: (626) 415-1488

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Exchange Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   EXOZ   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 8.01 — Other Events.

 

Attached is an Investor Presentation of eXoZymes Inc., a Nevada corporation, as of April 10, 2026, that is being provided to the potential underwriters and other offering participants for the proposed offering of securities by the Company.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibits   Description of Exhibit
     
99.1   Investor Presentation of eXoZymes Inc. for April 10, 2026.
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL Document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: April 10, 2026 EXOZYMES INC.
     
  By /s/ Fouad Nawaz
    Fouad Nawaz,
    Vice President, Finance

 

 

 

Exhibit 99.1

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 

Source: View Original Filing on SEC EDGAR

FAQ

What did eXoZymes Inc. (EXOZ) disclose in this 8-K filing?

eXoZymes Inc. disclosed that it prepared an investor presentation dated April 10, 2026. The presentation is being provided to potential underwriters and other participants in connection with a proposed offering of the company’s securities, giving them structured information about the business.

What is Exhibit 99.1 in eXoZymes Inc. (EXOZ) latest filing?

Exhibit 99.1 is an investor presentation of eXoZymes Inc. dated April 10, 2026. It is attached to the report to inform potential underwriters and other offering participants about the company in connection with a proposed securities offering.

What type of event is described in eXoZymes Inc. (EXOZ) Item 8.01?

Item 8.01 describes an “Other Events” disclosure in which eXoZymes Inc. notes its investor presentation. The company states this presentation is being provided to potential underwriters and other offering participants for a proposed offering of its securities.

Where is eXoZymes Inc. (EXOZ) headquartered according to the filing?

According to the filing, eXoZymes Inc. is headquartered at 750 Royal Oaks Drive, Suite 106, Monrovia, California 91016. The report also lists a company telephone number, indicating the location of its principal executive offices for investors and regulators.

On which exchange is eXoZymes Inc. (EXOZ) common stock listed?

The filing states that eXoZymes Inc.’s common stock is listed on the Nasdaq Capital Market. The trading symbol for the company’s common stock is EXOZ, confirming where investors can find and trade its shares in the public markets.

Filing Exhibits & Attachments

24 documents

Press Releases

Other Documents